FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer.
Ontology highlight
ABSTRACT: Primary objectives: compare the activity of panitumumab in combination with mFOLFOX6 or with mFOLFOXIRI in RAS and BRAF wt mCRC patients in terms of Overall Response Rate according to RECIST version 1.1
Primary endpoints: Distribution of overall response rate (ORR)ORR is defined as the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria, during the induction and the maintenance phases of treatment. The determination of clinical response will be based on investigator reported measurements. Responses will be evaluated every 8 weeks.
DISEASE(S): Metastatic Colorectal Cancer,Carcinoma Colorettale Metastatico
PROVIDER: 2536351 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA